Fetching results...
0 items found

A0535: The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211

D. Robesti, Milan (IT)
Robesti D.1, Nocera L.1, Belladelli F.1, Schultz J.G.2, Fallara G.1, Marandino L.3, Raggi D.3, Montorsi F.1, Necchi A.3, Martini A.4
1IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Urology, Dept. of Experimental Oncology, Milan, Italy, 2National Cancer Institute, National Institutes of Health, Bethesda, United States of America, 3IRCCS Ospedale San Raffaele, Dept. of Oncology, Milan, Italy, 4University of Texas, MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America
38th Annual EAU Congress
Date – Time - Location
12 March 2023, 10:45 - 12:15, Pink Area, Coral 3
Abstract Session 26 - Metastatic urothelial cancer: News in immunotherapy and more
Urothelial Cancer, metastatic - Treatment, Drug Treatment
  • © 2023 European Association of Urology
  • Disclaimer